ES2069588T3 - Formas de dosificacion oral de liberacion controlada a base de diferentes eteres de celulosa. - Google Patents

Formas de dosificacion oral de liberacion controlada a base de diferentes eteres de celulosa.

Info

Publication number
ES2069588T3
ES2069588T3 ES89308220T ES89308220T ES2069588T3 ES 2069588 T3 ES2069588 T3 ES 2069588T3 ES 89308220 T ES89308220 T ES 89308220T ES 89308220 T ES89308220 T ES 89308220T ES 2069588 T3 ES2069588 T3 ES 2069588T3
Authority
ES
Spain
Prior art keywords
eteres
cellulose
different
dosage forms
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89308220T
Other languages
English (en)
Inventor
David Emil Edgren
Judy A Magruder
Gurdish Kaur Bhatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ES2069588T3 publication Critical patent/ES2069588T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCUBRE UNA FORMA DE DOSIFICACION QUE CONTIENE UNA HIDROXIPROPILMETILCELULOSA DE BAJO NUMERO MEDIO DE PESO MOLECULAR, UNA HIDROXIPROPILMETILCELULOSA DE ALTO NUMERO DE PESO MEDIO MOLECULAR, Y UNA DROGA BENEFICIOSA.
ES89308220T 1987-04-06 1989-08-14 Formas de dosificacion oral de liberacion controlada a base de diferentes eteres de celulosa. Expired - Lifetime ES2069588T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/034,971 US4786503A (en) 1987-04-06 1987-04-06 Dosage form comprising parallel lamine
US07/039,405 US4871548A (en) 1987-04-06 1987-04-17 Controlled release dosage form comprising different cellulose ethers

Publications (1)

Publication Number Publication Date
ES2069588T3 true ES2069588T3 (es) 1995-05-16

Family

ID=39967167

Family Applications (2)

Application Number Title Priority Date Filing Date
ES8800932A Expired ES2006394A6 (es) 1987-04-06 1988-03-25 Un sistema bilaminado para liberar un farmaco beneficioso a un medio de uso.
ES89308220T Expired - Lifetime ES2069588T3 (es) 1987-04-06 1989-08-14 Formas de dosificacion oral de liberacion controlada a base de diferentes eteres de celulosa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES8800932A Expired ES2006394A6 (es) 1987-04-06 1988-03-25 Un sistema bilaminado para liberar un farmaco beneficioso a un medio de uso.

Country Status (21)

Country Link
US (3) US4786503A (es)
EP (1) EP0413061B1 (es)
JP (2) JP2916147B2 (es)
KR (1) KR950003918B1 (es)
AT (1) ATE116844T1 (es)
AU (1) AU601033B2 (es)
BE (1) BE1001699A3 (es)
CA (1) CA1331739C (es)
CH (1) CH677447A5 (es)
DE (2) DE3811114C2 (es)
ES (2) ES2006394A6 (es)
FR (1) FR2613224B1 (es)
GB (1) GB2203338B (es)
GR (1) GR1000053B (es)
IE (1) IE67156B1 (es)
IT (1) IT1219750B (es)
LU (1) LU87189A1 (es)
NL (1) NL8800867A (es)
PT (1) PT91442B (es)
SE (1) SE503611C2 (es)
ZA (1) ZA882034B (es)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
JP2921861B2 (ja) * 1989-07-05 1999-07-19 旭光学工業株式会社 オートフォーカスカメラ
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5037658A (en) * 1989-09-14 1991-08-06 Hoechst-Roussel Pharmaceuticals, Inc. Direct dry compressible acetaminophen composition
US5130140A (en) * 1989-09-14 1992-07-14 Hoeschst-Roussel Pharmaceuticals Inc. Method of making direct dry compressible acetaminophen composition
US5198228A (en) * 1989-09-14 1993-03-30 Hoechst-Roussel Pharmaceuticals Inc. Direct dry compressible acetaminophen tablet
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
IE64128B1 (en) * 1990-02-26 1995-07-12 Byrne Rynne Holdings Ltd A pharmaceutical composition
SE9003904D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
GB2260081B (en) * 1991-10-04 1995-11-29 Euro Celtique Sa Use of ibuprofen/codeine mixtures in treatment of chronic pain
GB9121204D0 (en) * 1991-10-04 1991-11-20 Euro Celtique Sa Medicament
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
CA2150119C (en) * 1992-11-30 2005-03-15 Robert C. Cuca Tastemasked pharmaceutical materials
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
AU707843B2 (en) * 1993-10-13 1999-07-22 Concordia Pharmaceuticals Inc. Extended release clonidine formulation
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
DE4408326A1 (de) † 1994-03-11 1995-09-14 Hexal Pharma Gmbh Retardtablette mit einem Gehalt an Diclofenac-Na
FR2723586A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Nouvelles compositions contenant de la cimetidine et associations en derivant
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US6471994B1 (en) 1995-01-09 2002-10-29 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
AU737464B2 (en) * 1995-01-09 2001-08-23 J. Rettenmaier & Soehne Gmbh + Co. Kg Pharmaceutical excipient having improved compressibility
US6936277B2 (en) * 1995-01-09 2005-08-30 J. Rettenmaier & Soehne Gmbh & Co. Kg Pharmaceutical excipient having improved compressibility
US6395303B1 (en) * 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
WO1997017951A1 (en) * 1995-11-14 1997-05-22 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US6852336B2 (en) 1995-11-15 2005-02-08 J. Rettenmaier & Soehne Gmbh + Co. Kg Directly compressible high load acetaminophen formulations
US6391337B2 (en) 1995-11-15 2002-05-21 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5789014A (en) * 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
CA2269880C (en) * 1996-05-09 2004-11-23 William A. Mallow Biocidal coating composition
US6280509B1 (en) 1996-05-09 2001-08-28 Alistagen Corporation Biocidal coating compositions and method
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
PT1003476E (pt) * 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
USD423141S (en) * 1998-03-20 2000-04-18 Colgate-Palmolive Company Detergent tablet
USD426020S (en) * 1998-03-20 2000-05-30 Colgate-Palmolive Company Detergent tablet
USD422749S (en) * 1998-03-20 2000-04-11 Colgate-Palmolive Company Detergent tablet
CA2581111A1 (en) * 1998-07-28 2000-02-10 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
WO2000018370A2 (en) * 1998-09-25 2000-04-06 Delsys Pharmaceutical Corporation Liquid pharmaceutical for oral delivery
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6109487A (en) * 1999-02-12 2000-08-29 Dart Industries Inc. Container with dispensing assembly
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6231650B1 (en) 1999-09-17 2001-05-15 Alistagen Corporation Biocidal coating composition
US20030219488A1 (en) * 1999-12-22 2003-11-27 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6767899B1 (en) * 2000-08-29 2004-07-27 Leiner Health Services Corp. Composition and method for treatment of conditions having an inflammatory component
SI1345595T1 (sl) * 2000-09-29 2007-08-31 Solvay Pharm Bv Farmacevtska oblika s podaljĺ anim sproĺ äśanjem, ki je neodvisna od ionske jakosti
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
US6607512B2 (en) * 2001-01-09 2003-08-19 Genzyme Corporation Device for delivery of liquid and gel-like surgical materials and methods for use thereof
FR2822378A1 (fr) * 2001-03-23 2002-09-27 Igen Ipsor Generiques Nouveau procede de realisation de comprimes bicouches a liberation controlee
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
CA2449415A1 (en) * 2001-04-20 2002-10-31 Lavipharm Laboratories Inc. Intraoral delivery of nicotine for smoking cessation
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003214551A1 (en) * 2002-04-11 2003-10-20 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of carbidopa and levodopa
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
NZ586198A (en) * 2003-09-26 2011-12-22 Alza Corp Oros push-stick sustained release dosage forms for controlled delivery of active agents
EP1708684A2 (en) * 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
CA2537103C (en) * 2003-11-04 2010-01-19 Shire Laboratories, Inc. Once daily dosage forms of trospium
JP2007510654A (ja) * 2003-11-04 2007-04-26 スパーナス ファーマシューティカルズ インコーポレイテッド 分極した酸素原子を有するポリマーを含むマトリクスからの正に荷電した薬理学的活性分子の徐放
AU2004289222B2 (en) 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
HUE043945T2 (hu) 2004-05-14 2019-09-30 Merck Sharp & Dohme Betegségek kezelése antibiotikumok használatával összefüggésben
US7897172B2 (en) * 2004-05-18 2011-03-01 L. Perrigo Company Tablets exhibiting reduced drug release variability
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
CN101068532B (zh) * 2004-09-30 2012-03-14 斯科尔医药公司 布洛芬改进释放剂型
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
CN1883456B (zh) * 2005-06-20 2010-12-15 常州市第四制药厂有限公司 掩味药物颗粒及其制备方法和用途
ES2366381T3 (es) * 2005-06-22 2011-10-19 Takeda Pharmaceutical Company Limited Comprimido que contiene un ingrediente activo difícilmente soluble.
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070218135A1 (en) * 2006-03-14 2007-09-20 Glenmark Pharmaceuticals Limited Sustained release matrix pharmaceutical composition
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
WO2009137827A2 (en) 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
EP2326310B1 (en) * 2008-08-15 2019-05-15 Assertio Therapeutics, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
ES2555927T3 (es) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
US9351924B2 (en) 2011-03-11 2016-05-31 Snu R&Db Foundation Drug delivery system including laminated structure
WO2012124869A1 (ko) * 2011-03-11 2012-09-20 서울대학교산학협력단 적층 구조를 포함하는 약물 전달 시스템
WO2013023250A1 (en) 2011-08-16 2013-02-21 Baker Idi Heart & Diabetes Institute Holdings Limited Controlled-release formulation
ES2639132T3 (es) * 2011-11-21 2017-10-25 Denka Company Limited Clínker de endurecimiento ultrarrápido, composición de cemento que utiliza el mismo, y método para producir el mismo
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3003297A4 (en) 2013-06-05 2017-04-19 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CA2971071A1 (en) 2014-12-22 2016-06-30 Cardiora Pty Ltd Use of milrinone and derivatives thereof in the treatment of heart failure with preserved ejection fraction (hfpef)
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
MX2020005707A (es) 2017-12-01 2020-08-20 Ultragenyx Pharmaceutical Inc Profarmacos de creatina, composiciones y metodos de uso de estos.
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
JPS57110254A (en) * 1980-12-29 1982-07-09 Teijin Ltd Coating agent of injured membrane part of oral cavity
JPS5839618A (ja) * 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd 持続性積層錠剤
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
US4553973A (en) * 1982-07-12 1985-11-19 Alza Corporation Process for preparing osmotic device
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
EP0227814A1 (en) * 1985-07-02 1987-07-08 The Upjohn Company Therapeutic formulations with bimodal release characteristics
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine

Also Published As

Publication number Publication date
KR950003918B1 (ko) 1995-04-20
JP2916147B2 (ja) 1999-07-05
ATE116844T1 (de) 1995-01-15
GR880100214A (en) 1989-01-31
FR2613224B1 (fr) 1990-12-07
US4871548A (en) 1989-10-03
AU601033B2 (en) 1990-08-30
LU87189A1 (fr) 1988-11-17
EP0413061B1 (en) 1995-01-11
KR880012212A (ko) 1988-11-26
PT91442B (pt) 1995-07-06
PT91442A (pt) 1990-03-08
SE503611C2 (sv) 1996-07-15
IE892845A1 (en) 1991-03-13
DE3811114C2 (de) 1996-05-30
CA1331739C (en) 1994-08-30
JPH0393731A (ja) 1991-04-18
ZA882034B (en) 1988-09-15
FR2613224A1 (fr) 1988-10-07
GB8807493D0 (en) 1988-05-05
DE3811114A1 (de) 1988-11-10
GB2203338B (en) 1991-07-17
US4786503A (en) 1988-11-22
US4946685A (en) 1990-08-07
NL8800867A (nl) 1988-11-01
IE67156B1 (en) 1996-03-06
IT1219750B (it) 1990-05-24
JPS63258808A (ja) 1988-10-26
EP0413061A1 (en) 1991-02-20
AU1406588A (en) 1988-10-06
IT8867302A0 (it) 1988-04-05
GB2203338A (en) 1988-10-19
BE1001699A3 (fr) 1990-02-13
GR1000053B (el) 1990-05-11
DE68920578D1 (de) 1995-02-23
DE68920578T2 (de) 1995-05-04
JPH0776181B2 (ja) 1995-08-16
ES2006394A6 (es) 1989-04-16
SE8801240D0 (sv) 1988-04-05
SE8801240L (sv) 1988-10-07
CH677447A5 (es) 1991-05-31

Similar Documents

Publication Publication Date Title
ES2069588T3 (es) Formas de dosificacion oral de liberacion controlada a base de diferentes eteres de celulosa.
GR910100283A (el) Στερεά από του στόματος χορηγουμένη φαρμακευτική μορφή δοσιμετρήσεως προγραμματισμένου ρυ?μού απελευ?ερώσεως.
ATE315021T1 (de) Pharmazeutische verbindungen
SE8701900L (sv) Pulsavgivning av lekemedel
ES2032770T3 (es) Un procedimiento para producir farmacos de administracion nasal.
CY1104982T1 (el) Απο toy στοματος λαμβανομενο στερεο παρασκευασμα
DE69129800D1 (de) Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin
SE8803486L (sv) Dosform foer behandling av kardiovaskulaera sjukdomar
IT1228685B (it) Indicatore del tempo di dosaggio di flaconi di medicinali e flacone per medicinali dotato di un simile indicatore.
DE3783394T2 (de) Arzneizubereitung zur oralen anwendung.
AR240013A1 (es) Una composicion tintorea de fibras queratinicas y dispositivo que la contiene.
AR026775A1 (es) Tampon digital, paquete que contiene tampones digitales y proceso para producir el tampon digital
MX9202804A (es) Composicion farmaceutica y terapeutica que comprende una nueva molecula de adhesion intracelular.
EE200200202A (et) Uudsed tritsüklilised ühendid, nende saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud HIV-nakkuse raviks, ning neid sisaldav farmatseutiline kompositsioon
ATE99165T1 (de) Mund- und zahnpflegemittel.
ES2051732T3 (es) Composiciones orales.
DE3766858D1 (de) Verpamil in dosierungskapsel.
ES2024053B3 (es) Un dispositivo para fijar una protesis dental.
IS4923A (is) Meðferðaráform við inngjöf á H+,K+-ATPasa-blokkara
GR1000261B (el) Μασητικο δισκιο φαρμακου το οποιο περιεχει μεσον για την επικαλυψη της γευσεως.
ES2054333T3 (es) Forma de dosificacion para administrar un antagonista del calcio.
FR2623714B1 (fr) Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
FI895520A0 (fi) Anti-aterosklerotiska diaryl foereningar.
AR246432A1 (es) Composiciones acuosas de fluoruro estannoso para la higiene bucal y metodo para su preparacion.
TR24895A (tr) PIRIMIDIN TüREVLERI,BUNLARIN ISTIHSAL EDILMESI VE KULLANILMASI

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 413061

Country of ref document: ES